The Link to Colorectal Cancer
One of the most concerning aspects of long-term IBD is the development of colitis-associated colorectal cancer. The chronic cycle of tissue damage and rapid cell regeneration creates an environment where genetic mutations are more likely to occur.
When examining tissue samples from patients with colorectal cancer caused by IBD, the Charité researchers found a particularly high concentration of oncostatin M receptors in the areas immediately surrounding the tumors. Interestingly, these receptors were not present in the same density in healthy surrounding tissue. This observation strongly suggests that the OSM signaling pathway not only drives inflammation but may also play a direct role in promoting the development and growth of cancer cells.
In experimental models, the team was able to specifically block the binding sites for oncostatin M. The results were highly encouraging, showing a clear reduction in both the severity of chronic inflammation and the subsequent development of cancerous lesions.
Toward a New Standard of Care
The transition from laboratory discovery to clinical application is often a long one, but for IBD patients, there is cause for optimism. Because the research identifies a specific receptor interaction, it provides a clear blueprint for drug development.
Professor Britta Siegmund, Director of the Clinic for Gastroenterology, Infectiology and Rheumatology at Charité, emphasizes the complexity of these diseases and the importance of this new data. "Chronic inflammatory bowel diseases are highly complex and differ from person to person. That’s exactly what makes them so difficult to treat and predict treatment," she says. "Thanks to the role of oncostatin M and its amplifying interaction with interleukin-22, which we have now identified, we have a clearer understanding of what drives chronic inflammation in some patients. This opens up the door to developing and testing a new therapeutic approach."
The findings are already moving toward real-world application. A clinical trial is currently underway to test the safety and efficacy of an antibody designed to block the receptors for oncostatin M. If successful, this therapy could provide a lifeline for "non-responders"—those patients for whom current medical science previously had no effective answers.
By specifically disrupting the harmful synergy between IL-22 and OSM, researchers hope to "douse the fire" of inflammation before it causes irreversible tissue damage or oncogenic shifts. For the thousands of young people diagnosed each year, this research represents a significant step toward a future where chronic bowel disease is not just managed, but effectively silenced.
